NASDAQ:BYSI

Beyondspring Stock News

Healthcare > Biotechnology

Buy BYSI

*Your capital is at risk

$1.74

+0.0400 (+2.35%)

At Close: Jun 03, 2026

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

07:00am, Tuesday, 02'nd Jun 2026

FLORHAM PARK, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the t

BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting

07:00am, Monday, 18'th May 2026

FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the tr

BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

07:00am, Wednesday, 13'th May 2026

AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First Mol

BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs

07:00am, Wednesday, 22'nd Apr 2026

New Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with Leading ADC Drugs — With or Without Immunotherapy

BeyondSpring (NASDAQ:BYSI) Stock Passes Above 50 Day Moving Average – Here’s Why

02:17am, Sunday, 05'th Apr 2026

BeyondSpring Inc. (NASDAQ: BYSI - Get Free Report) passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $1.52 and traded as high as $1.73. Be

BeyondSpring Files 2025 Annual Report on Form 10-K

04:30pm, Wednesday, 25'th Mar 2026

FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

07:15am, Monday, 09'th Feb 2026

FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today

Financial Contrast: Lisata Therapeutics (NASDAQ:LSTA) vs. BeyondSpring (NASDAQ:BYSI)

01:22am, Friday, 16'th Jan 2026

BeyondSpring (NASDAQ: BYSI - Get Free Report) and Lisata Therapeutics (NASDAQ: LSTA - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two co

Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI)

02:08am, Tuesday, 06'th Jan 2026

BeyondSpring (NASDAQ: BYSI - Get Free Report) and Cyclerion Therapeutics (NASDAQ: CYCN - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path

07:00am, Friday, 12'th Dec 2025

FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today a

BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript)

10:24am, Monday, 15'th Sep 2025

BeyondSpring Inc. (NASDAQ:BYSI ) 2025 Annual Shareholders Meeting Call September 15, 2025 9:00 AM EDT Company Participants Lan Huang - Co-Founder, Chairman & CEO Presentation Unknown Attendee Good mor

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

07:00am, Monday, 07'th Jul 2025

FLORHAM PARK, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) today announced publication of a human clinical study in Med (Cell Press) demonstrating that Plinabulin, when c

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

07:00am, Tuesday, 03'rd Jun 2025

FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developin

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

04:30pm, Monday, 12'th May 2025

FLORHAM PARK, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical‑stage global biopharmaceutical company focused on developing cancer therapeutics, today announced it

BeyondSpring Files 2024 Annual Report on Form 10-K

07:05am, Thursday, 27'th Mar 2025

FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovati

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by